 Final report French multicenter phase II study nitrosourea fotemustine evaluable patients disseminated malignant melanoma patients cerebral metastases sixty-nine patients histologic evidence disseminated malignant melanoma patients cerebral metastases Phase II study nitrosourea fotemustine treatment regimen hour IV infusion week consecutive weeks rest period induction therapy patients maintenance therapy weeks disease fifty-three patients evaluable response complete responses partial responses World Health Organization criteria objective response rate confidence interval Responses cerebral visceral nonvisceral metastatic sites median duration response weeks range weeks objective response rate untreated patients patients main toxicity hematologic delayed reversible leukopenia and/or thrombopenia objective response rate untreated patients activity cerebral metastases small amount extra-hematologic toxicity fotemustine effective drug disseminated malignant melanoma